{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:29:40Z","timestamp":1772242180357,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.transci.2025.104174","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T11:09:45Z","timestamp":1749294585000},"page":"104174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Relapse and beyond: Navigating the long-term clinical impacts of immune thrombotic thrombocytopenic purpura"],"prefix":"10.1016","volume":"64","author":[{"given":"Minh-Ha","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8348-4893","authenticated-orcid":false,"given":"Jesse","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2025.104174_bib1","first-page":"331","article-title":"Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura","volume":"117","author":"Kubo","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.transci.2025.104174_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158137","article-title":"ADAMTS13 in the new era of TTP","volume":"25","author":"Papakonstantinou","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.transci.2025.104174_bib3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.transci.2025.104174_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/oxfordjournals.jbchem.a003009","article-title":"A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von willebrand factor-cleaving protease?","volume":"130","author":"Soejima","year":"2001","journal-title":"J Biochem"},{"key":"10.1016\/j.transci.2025.104174_bib5","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2011-02-306597","article-title":"Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von willebrand factor","volume":"118","author":"Crawley","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib6","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1126\/science.1170905","article-title":"Mechanoenzymatic cleavage of the ultralarge vascular protein von willebrand factor","volume":"324","author":"Zhang","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.transci.2025.104174_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-med-061813-013241","article-title":"ADAMTS13 and von willebrand factor in thrombotic thrombocytopenic purpura","volume":"66","author":"Zheng","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.transci.2025.104174_bib8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2025.104174_bib9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jtha.2022.11.010","article-title":"Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura","volume":"21","author":"Volker","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2025.104174_bib10","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Hovinga","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib11","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","article-title":"Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity","volume":"109","author":"Ferrari","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2025.104174_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12185-023-03657-0","article-title":"Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023","volume":"118","author":"Matsumoto","year":"2023","journal-title":"Int J Hematol"},{"key":"10.1016\/j.transci.2025.104174_bib14","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/jth.15009","article-title":"Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2025.104174_bib15","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2025.104174_bib16","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2025.104174_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/hematology.2020000164","article-title":"Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura","volume":"2020","author":"Li","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.transci.2025.104174_bib19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/blood.2021014514","article-title":"How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge","volume":"140","author":"Akwaa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib20","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.2022017023","article-title":"Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy","volume":"141","author":"Doyle","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib23","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib24","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood.2022016640","article-title":"Race, rituximab, and relapse in TTP","volume":"140","author":"Chaturvedi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib25","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood.2023023780","article-title":"Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange","volume":"144","author":"Kuhne","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tmrv.2022.09.001","article-title":"Plasma cell directed therapy for immune thrombotic thrombocytopenic purpura (iTTP)","volume":"36","author":"Chen","year":"2022","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2025.104174_bib27","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjh.19035","article-title":"Bortezomib in relapsed\/refractory immune thrombotic thrombocytopenic purpura: a single-centre retrospective cohort and systematic literature review","volume":"204","author":"Lee","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2025.104174_bib28","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMoa2402567","article-title":"Recombinant ADAMTS13 for immune thrombotic thrombocytopenic purpura","volume":"390","author":"Bendapudi","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2025.104174_bib29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/asheducation-2018.1.548","article-title":"TTP: long-term outcomes following recovery","volume":"2018","author":"George","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.transci.2025.104174_bib30","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2019.226423","article-title":"Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura","volume":"105","author":"Riva","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2025.104174_bib31","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood-2019-128989","article-title":"Impact of residual effects and complications of thrombotic thrombocytopenic purpura (TTP) on daily living: a qualitative study","volume":"134","author":"Terrell","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1537-2995.2008.01938.x","article-title":"Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura","volume":"49","author":"Lewis","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2025.104174_bib33","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood.2023021974","article-title":"Reduction of mortality, cardiac damage, and cerebral damage by IL-1 inhibition in a murine model of TTP","volume":"143","author":"Muller","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib34","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1182\/bloodadvances.2020004169","article-title":"Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission","volume":"6","author":"Sukumar","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2025.104174_bib35","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib36","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24138","article-title":"Increased morbidity during long-term follow-up of survivors of thrombotic thrombocytopenic purpura","volume":"90","author":"Chaturvedi","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2025.104174_bib38","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/ajh.26341","article-title":"Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura","volume":"96","author":"Brodsky","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2025.104174_bib39","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1537-2995.2009.02101.x","article-title":"Cognitive deficits after recovery from thrombotic thrombocytopenic purpura","volume":"49","author":"Kennedy","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2025.104174_bib40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/bjh.17126","article-title":"Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura","volume":"191","author":"Alwan","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2025.104174_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.21881","article-title":"Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura","volume":"86","author":"Cataland","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2025.104174_bib42","first-page":"325","article-title":"Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognition","volume":"142","author":"Chaturvedi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.transci.2025.104174_bib43","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/bjh.19246","article-title":"Cognitive decline in thrombotic thrombocytopenic purpura survivors: the role of White matter health as assessed by MRI","volume":"204","author":"Hannan","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2025.104174_bib44","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/trf.14060","article-title":"Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura","volume":"57","author":"Falter","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2025.104174_bib45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2017.01.003","article-title":"Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura","volume":"151","author":"Chaturvedi","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.transci.2025.104174_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1137019","article-title":"Immune thrombotic thrombocytopenic purpura: spotlight on long-term outcomes and survivorship","volume":"10","author":"Selvakumar","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.transci.2025.104174_bib47","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1055\/s-0037-1619783","article-title":"Autoimmune disorders in patients with idiopathic thrombotic thrombocytopenic purpura","volume":"32 1","author":"John","year":"2012","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.transci.2025.104174_bib48","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001598","article-title":"Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura","volume":"94","author":"Roriz","year":"2015","journal-title":"Medicine"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:17:37Z","timestamp":1753352257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050225001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1473050225001119"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2025.104174","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relapse and beyond: Navigating the long-term clinical impacts of immune thrombotic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2025.104174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104174"}}